Speakers

Jill E. McCutcheon
Brigitte GoulardThe marriage of insurance and technology presents a way for intermediaries and insurers to reinvent how they do business. With the industry now perched on the cusp of an insurtech revolution, the market is experiencing the next wave of efficient products and transparent processes.
Jill McCutcheon and Brigitte Goulard discuss the current state of play for the insurance industry in Canada, including:
Click here to see other videos and webinars in this series
Brigitte Goulard (00:06): Jill, why don't you tell us a little bit about the success of insurtech in Canada? Has it been very successful?
Jill McCutcheon (00:13): So it's a great question because we sure hear a lot about insurtech. I mean, every industry paper, every industry conference we hear about insurtech. And of course, it covers the whole spectrum, from buying, to administration, to termination, to claims. I would say, though, that at least in the connection with the buying of insurance, probably less than 2% of transactions are concluded digitally or on the on the web. So it's been a little slow in the uptake. But of course, it's very important to the future of insurance industry participants that they have a foot in the door with insurtech.
Jill McCutcheon (00:59): Part of the reasons it's been slow is that we have a lot of different regulators in Canada for insurance. We, in fact, have 17 of them. And there's a lot of them. And they all like to make their own rules or they all have their own laws with slightly different requirements. And so that has made it, I think, a little more difficult for insurtechs to take hold because they have to have a solution that works across the whole country, which they can't always achieve. So an example would be... Brigitte, you have a car accident at the side of the road, you're asked for your proof of insurance, and in some provinces you can show that proof on your phone, but in other provinces you couldn't. Some provinces don't allow for electronic proof of insurance.
Brigitte Goulard (01:51): It must be frustrating for companies with whom you deal with that operate across Canada and have kind of this patchwork of what can be done. Does that mean they just abandon the idea until it's spread throughout the provinces? Or do they do the patchwork?
Jill McCutcheon (02:08): So that's a great question actually, because in Ontario, there is a patchwork. There's no question. And it is frustrating because we have a lot of foreign insurance intermediaries and companies, or fintech firms that are coming to invest in what is otherwise viewed as an attractive market. And then you run into these minuscule rule differences in each and every jurisdiction, which very much make the architecture for these insurtech solutions more challenging. But interestingly, in Ontario we have a regulatory sandbox which FSRA [Financial Services Regulatory Authority of Ontario] is working with, so FSRA has the power to give you exemptive relief from certain provisions of the Insurance Act, for example, the obligation to be licensed, right? As an insurance intermediary, they could waive that provision for the purposes of allowing you to test your insurtech solution. So they are actually looking for people to use the sandbox. So if you know of anybody in the insurtech space, anybody that needs to try something out in a developed market in Ontario with a lighter regulatory burden, Ontario would be the place to come.
Brigitte Goulard (03:28): So it's interesting that you're talking about this patchwork. Have they just started discussing what they can do in terms of insurtech to facilitate this?
Jill McCutcheon (03:36): So they get together in two forums, the Canadian Council of Insurance Regulators and CISRO [Canadian Insurance Services Regulatory Organizations], which is the councils that you referred to, that deal with the licensing of intermediaries. And what's happened when CISRO got together, I think what you're referring to, they've agreed upon a group of principles called the “Fair Treatment of Customers”. The long and the short of it being that the product needs to be suitable throughout the lifetime of the product with the customer, not just at the point of sale, and that the product features need to be, you know, clearly described. I mean, these principles all come from the IAIS Core Principle 19 around Fair Treatment of Customers, and it's been picked up in Canada. And compliance people really like to talk about FTC. They just call Fair Treatment of Customers, “FTC”. The thing about it is it's a bit tricky for lawyers because they are very lofty principles and they're not necessarily set out in a law or a regulation or a rule. So sometimes it gets a little tricky to tell whether you're in compliance with these principles and, quite frankly, whether you need to be in compliance with these principles from tip-to-toe. And then CISRO, which is the ones that regulate the intermediaries, has gone further to adopt a code of conduct for insurance intermediaries. And it's really the logical extension to the Fair Treatment of Customers principles as it relates to intermediaries. So there are two provinces that have taken it sort of to the next level. So, Québec has the code of commercial practices, which is incorporated into the legislation and very much adopts Fair Treatment of Customer principles. So always a good place to go, the commercial practices code just because it is a bit more clear if you look at that code, and then British Columbia is going to be adopting something into a rule. And so we'll have something a little more concrete when those things are completed.
Brigitte Goulard (05:54): And how those rules transfer to insurtech? Like Fair Treatment of Customers, as you say, is very lofty and touch basically any type of interaction you may have with your clients.
Jill McCutcheon (06:08): Insurtech I think represents an opportunity for intermediaries and insurers to make FTC a reality.
Brigitte Goulard (06:18): I see, okay.
Jill McCutcheon (06:18): In other words, if you need information about a product or your circumstances have changed or, you know, you want to administer claims in a more transparent fashion, like my personal belief is that technology is absolutely providing a solution. So a really good example would be now when you have a car accident, most insurance companies, through their adjusters, have an insurtech solution where you can see the progress of your claim as it's being adjusted. Previously an adjuster came, looked at your car, you know, got you to sign a proof of loss, and then you waited to hear the next step, which could have been weeks and weeks. And so insurtech, I think, is absolutely representing a way to take it to the next level when it comes to transparency with our customers, which is a core part of the FTC principles.
Brigitte Goulard (07:15): So it's very good for customers for sure. It must also be good for the insurance company because they can have a better process. But is it good when there's an issue from a legal perspective, like isn't there more documentation that you would have to go through or different rules? What's the impact of regtech, for example, for lawyers?
Jill McCutcheon (07:39): Well actually, I'm going to probably rephrase your question. So what's going on with respect to Fair Treatment of Customers, which is connected to insurtech is that there is a survey out that the AMF is leading on behalf of CCIR, Canadian Council of Insurance Regulators, and they're asking a lot of questions about how Fair Treatment of Customers principles are embedded into everything you do, including absolutely, your technology solutions. But in inside those questions you can see they want insurers to adopt a public commitment to Fair Treatment of Customers. I see legal risk in that—
Brigitte Goulard (08:19): Yes, absolutely. Yes.
Jill McCutcheon (08:20): And so it is related to insurtech because, of course, it is how insurers and intermediaries will take their customer service to the next level. But a public commitment to these lofty principles strikes me as posing a risk, because there’s always going to be someone who thinks that you didn’t quite meet that standard. It could be a cause for a class action, it could be a lot of reasons. But I think what the industry response has been is to say, look, we have the principles of Fair Treatment of Customers embedded in everything we do, in our producer code of conduct, in our business code of conduct, in our conflict of interest code, you know, in our complaint handling procedures. So we don't need a separate public commitment.
Brigitte Goulard (09:13): At the beginning when we started talking, you were saying how little there's been usage, and most of it is because it's a patchwork. So how long do you think it's going to be before we actually see real progress? That we can see that things are happening at a scale, where it's scalable that communities can use it?
Jill McCutcheon (09:31): Yeah, I mean, I think it's starting slow in terms of how many people actually buy over the internet, but it is much quicker in certain other areas on the backend, like around administration because it's a given that an insurer will save money if they can make the claims process more efficient, and they have control over that process, right? I mean, a lot of insurers are intermediary-driven, and they don't have control over the sales process. It is going to take off, there's no question in the next 10 years it's going to be revolutionary. In the next 10 years, certain technological developments will help to accelerate that. I think it's a given it's going to happen. I just can't tell you if it's next week or if it's, you know.
Brigitte Goulard (10:18): Yes.
Jill McCutcheon (10:18): And I think between big data and artificial intelligence, insurance is ripe for revolution. I don’t think there’s any doubt.
Brigitte Goulard (10:26): Yes. And you're right there! To help them revolutionize.
Jill McCutcheon (10:30): Oh, absolutely. Yeah, we love that stuff.
Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.
Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.
Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.
La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.
Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.
Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.